Update (4:25 p.m.): Updated with Tuesday market close information.
But the stock plunged in the afternoon after TheStreet's Adam Feuerstein wrote CEO Joseph Kim is trying to curb expectations for the soon-to-be-announced results from its phase II study of its DNA vaccine VGX-3100 in women with cervical pre-cancerous lesions.
The stock closed down 13.36%, or $1.44, to $9.34. More than 11.3 million shares changed hands, which surpassed the average volume of 1,521,180.
For more on this story, read Feuerstein's article here.